Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Fausto Castagnetti et al.|Oncotarget|2016Cited by 35
CO-OCCURRENCE OF JAK2/CALR-POSITIVE MYELOPROLIFERATIVE DISORDER AND BCR-ABL-POSITIVE CHRONIC MYELOGENOUS LEUKAEMIA TREATED WITH COMBINATION OF TYROSINE KINASE INHIBITORS AND RUXOLITINIB.Katia Paciaroni, Tommaso Caravita di Toritto, Nicoletta Villivà et al.|Mediterranean Journal of Hematology and Infectious Diseases|2025Cited by 0